

Paper No. _____
Filed: May 26, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
INNOPHARMA INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS
INC., and MYLAN INC.,
Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
BAUSCH & LOMB PHARMA HOLDINGS CORP.,
Patent Owner

Case IPR2015-00902
U.S. Patent 8,669,290

PATENT OWNER'S UPDATED EXHIBIT LIST

Further to 37 C.F.R. § 42.63(e), Patent Owner Senju Pharmaceutical Co., Ltd., hereby submits a current listing of Senju Exhibits to counsel for Petitioner InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., InnoPharma LLC, Mylan Pharmaceuticals Inc., and Mylan Inc.

| Exhibits | Description |
|-----------------|---|
| Exhibit 2001 | Transcript of Teleconference with the Board, dated April 15, 2015. |
| Exhibit 2002 | U.S. Patent No. 8,669,290 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.” |
| Exhibit 2003 | U.S. Patent No. 8,754,131 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.” |
| Exhibit 2004 | U.S. Patent No. 8,871,813 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.” |
| Exhibit 2005 | U.S. Patent No. 8,927,606 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.” |
| Exhibit 2006 | InnoPharma’s Paragraph IV Notice Letter dated September 19, 2014. |
| Exhibit 2007 | InnoPharma’s Paragraph IV Notice Letter dated October 30, 2014. |
| Exhibit 2008 | InnoPharma’s Paragraph IV Notice Letter dated March 27, 2015. |
| Exhibit 2009 | Complaint, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 14-cv-06893 (D.N.J. Nov. 3, 2014), ECF No. 1. |
| Exhibit 2010 | Complaint, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 15-cv-03240 (D.N.J. May 8, 2015), ECF No. 1. |
| Exhibit 2011 | Consolidated scheduling order, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 14-cv-06893 (D.N.J. April 16, 2015), ECF No. 30. |
| Exhibit 2012 | Amended scheduling order, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-00667 (D.N.J. Feb. 27, 2015), ECF No. 63. |
| Exhibit 2013 | Prolensa® (bromfenac ophthalmic solution 0.07%) Prescribing Information. |

| | |
|--------------|--|
| Exhibit 2014 | U.S. Patent No. 5,630,793 to Rowe, “Aqueous Ophthalmic Sprays.” |
| Exhibit 2015 | Press Release by Bausch + Lomb, dated April 8, 2013, entitled “Bausch + Lomb Receives FDA Approval for Prolensa™ (bromfenac ophthalmic solution) 0.07%.” |
| Exhibit 2016 | Lupin’s Paragraph IV Notice Letter dated May 13, 2014. |
| Exhibit 2017 | Metrics’ Paragraph IV Notice Letter dated June 26, 2014. |
| Exhibit 2018 | Paddock’s Paragraph IV Notice Letter dated December 15, 2014. |
| Exhibit 2019 | Apotex’s Paragraph IV Notice Letter dated December 10, 2014. |
| Exhibit 2020 | Masson et al., <i>Stabilisation of ionic drugs through complexation with non-ionic and ionic cyclodextrins</i> , 164 INT’L J. PHARMACEUTICS 45 (1998). |
| Exhibit 2021 | Loftsson et al., <i>Pharmaceutical Applications of Cyclodextrins</i> , 85 J. PHARMACEUTICAL SCIENCES 1017 (1996). |
| Exhibit 2022 | HSBC Global Research Lupin Company Report, Feb. 3, 2014, http://www.lupin.com/pdf/14/20140203%20-%20Lupin%203QFY14%20-%20HSBC.pdf |
| Exhibit 2023 | APOTEX ALL PRODUCTS, https://www.apotex.com/us/en/products/search.asp?qt=All&q=&t=All%20Products . |
| Exhibit 2024 | Consent judgment, <i>Senju Pharm. Co., Ltd. et al. v. Apotex Inc. et al.</i> , No. 15-cv-00336 (D.N.J. May 18, 2015), ECF No. 26. |
| Exhibit 2025 | U.S. Patent No. 5,856,345 to Doi et al., “Method for Stabilizing Pranoprofen and Stable Liquid Preparation of Pranoprofen.” |
| Exhibit 2026 | Xibrom® Prescribing Information. |
| Exhibit 2027 | Bromday® Prescribing Information. |
| Exhibit 2028 | Drugs@FDA, Listing of FDA-approved bromfenac ophthalmic solution 0.09% products, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=BROMFENAC%20SO DIUM . |
| Exhibit 2029 | Sheryl Gay Stolberg, <i>New Painkiller is Withdrawn After 4 Deaths</i> , N.Y. TIMES, Jun. 23, 1998. |
| Exhibit 2030 | Baklayan et al., <i>The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model</i> , CLINICAL OPHTHALMOLOGY 1717 (2014). |

Respectfully submitted,

Dated: May 26, 2015

By: /Bryan C. Diner/
Bryan C. Diner, Lead Counsel
Reg. No. 32,409

Counsel for Patent Owner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **Patent Owner's Updated Exhibit List and Exhibits 2002 - 2030** were served on May 26, 2015, via email directed to counsel of record for the Petitioner at the following:

Jitendra Malik
jitty.malik@alston.com

Bryan Skelton
bryan.skelton@alston.com

Lance Soderstrom
lance.soderstrom@alston.com

Date: May 26, 2015

/Ashley F. Cheung/
Ashley F. Cheung
Case Manager

Finnegan, Henderson, Farabow, Garrett &
Dunner, LLP